Oral mucositis is a common, treatment-limiting, and costly side effect of cancer treatments whose biological underpinnings remain poorly understood. In this study, mucositis induced in hamsters by 5-fluorouracil (5-FU) was observed after cheek-pouch scarifications, with and without administration of RGTA (RG1503), a polymer engineered to mimic the protective effects of heparan sulfate. RG1503 had no effects on 5-FU-induced decreases in body weight, blood cell counts, or cheek-pouch and jejunum epithelium proliferation rates, suggesting absence of interference with the cytotoxic effects of 5-FU. Extensive mucositis occurred in all of the untreated animals, and consisted of severe damage to cheek pouch tissues (epithelium, underlying connective tissue, and muscle bundles). Only half of the RG1503-treated animals had mucositis, over a mean area 70% smaller than in the untreated animals. Basement membranes were almost completely destroyed in the untreated group but was preserved in the RG1503 group. Mucositis is a common and debilitating side effect of radiation therapy and chemotherapy for cancer.1 The lesions develop in the oral and gastrointestinal tract mucosae, most notably at nonkeratinized sites. Mucositis of the oral cavity affects the cheeks, lips, soft palate, ventral surface of the tongue, and mouth floor. The ulcerative lesions are painful, restrict food intake, and often act as a portal of entry for indigenous oral flora.2 Mucositis is a source of morbidity, adversely affects quality of life, and incurs substantial economic cost. The risk of mucositis is influenced by the diagnosis, patient age, pre-existing oral health, and type and frequency of treatment administration.3